CN111286488A - In vitro culture method of natural killer cells - Google Patents
In vitro culture method of natural killer cells Download PDFInfo
- Publication number
- CN111286488A CN111286488A CN202010163641.4A CN202010163641A CN111286488A CN 111286488 A CN111286488 A CN 111286488A CN 202010163641 A CN202010163641 A CN 202010163641A CN 111286488 A CN111286488 A CN 111286488A
- Authority
- CN
- China
- Prior art keywords
- culture
- medium
- culture flask
- proliferation
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 43
- 238000000338 in vitro Methods 0.000 title claims abstract description 21
- 238000012136 culture method Methods 0.000 title claims abstract description 6
- 238000000576 coating method Methods 0.000 claims abstract description 42
- 239000011248 coating agent Substances 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 38
- 230000006698 induction Effects 0.000 claims abstract description 37
- 230000035755 proliferation Effects 0.000 claims abstract description 36
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 22
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 22
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims abstract description 19
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims abstract description 19
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims abstract description 19
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 18
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 18
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 18
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims abstract description 17
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims abstract description 17
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims abstract description 17
- 108010056030 retronectin Proteins 0.000 claims abstract description 17
- 230000008569 process Effects 0.000 claims abstract description 16
- 239000001963 growth medium Substances 0.000 claims abstract description 12
- 108010024636 Glutathione Proteins 0.000 claims abstract description 11
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 11
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960003180 glutathione Drugs 0.000 claims abstract description 11
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960001285 quercetin Drugs 0.000 claims abstract description 11
- 235000005875 quercetin Nutrition 0.000 claims abstract description 11
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 11
- 229940046009 vitamin E Drugs 0.000 claims abstract description 11
- 239000011709 vitamin E Substances 0.000 claims abstract description 11
- 239000002609 medium Substances 0.000 claims description 51
- 239000000243 solution Substances 0.000 claims description 35
- 239000006285 cell suspension Substances 0.000 claims description 15
- 210000005259 peripheral blood Anatomy 0.000 claims description 15
- 239000011886 peripheral blood Substances 0.000 claims description 15
- 210000005087 mononuclear cell Anatomy 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- 235000020776 essential amino acid Nutrition 0.000 claims description 13
- 239000003797 essential amino acid Substances 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 10
- 239000002504 physiological saline solution Substances 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 108010002616 Interleukin-5 Proteins 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000013589 supplement Substances 0.000 claims description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 5
- 229920001917 Ficoll Polymers 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000007640 basal medium Substances 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 5
- 230000004913 activation Effects 0.000 abstract description 2
- 230000003321 amplification Effects 0.000 abstract description 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 14
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
技术领域technical field
本发明涉及生物制药技术领域,具体涉及一种自然杀伤细胞体外培养方法。The invention relates to the technical field of biopharmaceuticals, in particular to a method for culturing natural killer cells in vitro.
背景技术Background technique
人体免疫系统是由一个复杂的机制调节的,当免疫系统发生异常时,可能会引起免疫系统的失衡,并可能发生癌症等各种难治疗的疾病。因此,免疫细胞疗法的发展成为人们关注的焦点,它是一种通过缓解免疫系统失衡并恢复正常状态来治疗免疫相关疾病的方法。The human immune system is regulated by a complex mechanism. When the immune system is abnormal, it may cause an imbalance of the immune system, and various difficult-to-treat diseases such as cancer may occur. Therefore, the development of immune cell therapy, a method of treating immune-related diseases by alleviating the imbalance of the immune system and restoring it to a normal state, has come into the spotlight.
自然杀伤细胞(NK)是人体免疫细胞的一种,来源于骨髓淋巴细胞。在人体中,NK细胞主要分布在外周血和脾脏中,大致占外周血淋巴细胞的5%~15%;同时,也少量存在于淋巴结等其他组织中。NK细胞相对于其他类型的淋巴细胞,具有其自身的独特性质。其最重要的特性是NK细胞不表达特异性抗原识别受体。因此,NK细胞在杀伤靶细胞的过程中,不需要通过特异性的机制识别靶细胞,是人体快速抵抗外源物质入侵的第一道防线,可以广谱地杀灭各种病原物。同时,NK细胞的杀伤作用不受主要组织相容性复合体的限制,可以对多种肿瘤细胞迅速杀伤和溶解。近年来有大量的临床研究表明NK细胞在抵抗肿瘤和病毒感染方面具有非常重要的作用。Natural killer cells (NK) are a type of human immune cells derived from bone marrow lymphocytes. In the human body, NK cells are mainly distributed in peripheral blood and spleen, accounting for approximately 5% to 15% of peripheral blood lymphocytes; at the same time, they also exist in small amounts in other tissues such as lymph nodes. NK cells have their own unique properties relative to other types of lymphocytes. Its most important property is that NK cells do not express specific antigen-recognition receptors. Therefore, in the process of killing target cells, NK cells do not need to recognize target cells through a specific mechanism. They are the first line of defense for the human body to quickly resist the invasion of foreign substances, and can kill various pathogens broadly. At the same time, the killing effect of NK cells is not limited by the major histocompatibility complex, and can rapidly kill and dissolve a variety of tumor cells. In recent years, a large number of clinical studies have shown that NK cells play a very important role in resisting tumors and viral infections.
由于在外周血淋巴细胞中NK细胞含量只有10%左右,因此在临床应用的NK细胞通常需要通过体外培养的方法进行扩大培养以满足临床用量。体外培养常规方法是采用高剂量IL-2扩增NK细胞,只能扩增几十倍,并且需要抽取患者大量的外周血,才能够达到治疗所需的细胞数量。因此,近年来,人们针对提高NK细胞体外培养效率进行了大量的研究,包括在培养基中加入IL-5、IL-21、GM-CSF等诱导因子和增值因子。这些针对培养基改进的方式虽然在一定程度上提高了NK细胞的扩增效率,但是将体外培养的NK细胞注射如体内发挥其免疫功能还需要确保NK细胞具有高的活性。由此,如何在提高NK细胞提高扩增效率的同时,防止细胞死亡和老化,保持细胞的活性,成为了目前亟待解决的技术问题。Since the content of NK cells in peripheral blood lymphocytes is only about 10%, NK cells used in clinical applications usually need to be expanded by in vitro culture to meet the clinical dosage. The conventional method of in vitro culture is to use high doses of IL-2 to expand NK cells, which can only be expanded several times, and a large amount of peripheral blood needs to be drawn from patients to achieve the number of cells required for treatment. Therefore, in recent years, people have carried out a lot of research to improve the efficiency of NK cell culture in vitro, including adding IL-5, IL-21, GM-CSF and other inducing factors and proliferating factors to the culture medium. Although these methods of improving the medium have improved the expansion efficiency of NK cells to a certain extent, the injection of NK cells cultured in vitro to exert their immune function in vivo also needs to ensure that the NK cells have high activity. Therefore, how to improve the expansion efficiency of NK cells, prevent cell death and aging, and maintain cell activity has become an urgent technical problem to be solved.
发明内容SUMMARY OF THE INVENTION
为了克服现有技术的缺陷,本发明的目的是提供一种自然杀伤细胞体外培养方法,具有高的扩增效率,保持细胞活性。In order to overcome the defects of the prior art, the purpose of the present invention is to provide a method for culturing natural killer cells in vitro, which has high amplification efficiency and maintains cell activity.
为了实现上述目的,本发明采用的技术方案如下:In order to achieve the above object, the technical scheme adopted in the present invention is as follows:
一种自然杀伤细胞体外培养方法,包括以下操作步骤:A method for culturing natural killer cells in vitro, comprising the following steps:
1)制备单个核细胞悬浮液:1) Prepare a mononuclear cell suspension:
将分离获得外周血单个核细胞重悬于诱导培养基中,得到单个核细胞悬浮液;Resuspend the isolated peripheral blood mononuclear cells in the induction medium to obtain a mononuclear cell suspension;
2)诱导培养:2) Induction culture:
在培养瓶中加入透明质酸和CD16抗体对培养瓶进行包被,作为诱导培养用培养瓶;将步骤1)的单个核细胞悬浮液接种至诱导培养用培养瓶中,培养24小时,培养过程中及时补充诱导培养基,并且每间隔6小时,向培养瓶中加入维生素E和槲皮素,获得诱导培养悬浮液;Add hyaluronic acid and CD16 antibody to the culture flask to coat the culture flask and use it as a culture flask for induction culture; inoculate the mononuclear cell suspension of step 1) into the culture flask for induction culture, and cultivate for 24 hours. Supplement the induction medium in time, and add vitamin E and quercetin to the culture flask every 6 hours to obtain the induction culture suspension;
3)增殖培养:3) Proliferation culture:
在新的培养瓶中加入芝麻素和RetroNectin对培养瓶进行包被,作为增殖培养用培养瓶;将步骤2)获得的诱导培养悬浮液接种至增殖培养用培养瓶中,在增殖培养基环境下培养14天,培养过程中及时补充增殖培养基,并且每间隔2~3天,向培养瓶中加入谷胱甘肽和卟啉-α,即完成;Add sesamin and RetroNectin to a new culture flask to coat the culture flask as a culture flask for proliferation culture; inoculate the induced culture suspension obtained in step 2) into a culture flask for proliferation culture, under the environment of proliferation culture medium Cultivate for 14 days, supplement the proliferation medium in time during the cultivation process, and add glutathione and porphyrin-α to the culture flask every 2 to 3 days, that is, complete;
其中诱导培养基的组成包括基础培养基、IL-2、IL-5、自体血清、氨基酸;增殖培养基的组成包括基础培养基、IL- 15、GM-CSF、自体血清、氨基酸。The composition of the induction medium includes basal medium, IL-2, IL-5, autologous serum, and amino acids; the composition of the proliferation medium includes basal medium, IL-15, GM-CSF, autologous serum, and amino acids.
进一步的,步骤2)中在培养瓶中加入透明质酸和CD16抗体对培养瓶进行包被的具体方法包括取生理盐水,加入透明质酸和CD16抗体,配置成含有3~6mg/ml透明质酸和5~8μg/ml CD16抗体的包被液,在培养瓶中加入5~10ml的PBS、1~2ml的包被液,4℃过夜后,弃去包被液,用PBS洗涤,即完成。Further, in step 2), the specific method of adding hyaluronic acid and CD16 antibody to the culture flask to coat the culture flask includes taking physiological saline, adding hyaluronic acid and CD16 antibody, and configuring it to contain 3-6 mg/ml hyaluronic acid. Acid and 5~8μg/ml CD16 antibody coating solution, add 5~10ml PBS and 1~2ml coating solution to the culture flask, after overnight at 4°C, discard the coating solution, wash with PBS, and you are done .
进一步的,步骤3)中在培养基中加入芝麻素和RetroNectin对培养瓶进行包被的具体方法包括取生理盐水,加入芝麻素和RetroNectin,配置成含有50~60μg/ml芝麻素和5~8μg/ml RetroNectin的包被液,在培养瓶中加入5~10ml的PBS、1~2ml的包被液,4℃过夜后,弃去包被液,用PBS洗涤,即完成。Further, in step 3), adding sesamin and RetroNectin to the culture medium, the specific method for coating the culture flask includes taking physiological saline, adding sesamin and RetroNectin, and being configured to contain 50-60 μg/ml sesamin and 5-8 μg /ml RetroNectin coating solution, add 5~10ml of PBS and 1~2ml of coating solution to the culture flask. After overnight at 4°C, discard the coating solution and wash with PBS.
进一步的,诱导培养基的具体组成为:DMEM培养基,5%自体血清,1%谷氨酰胺,1%非必需氨基酸,500~750IU/ml IL-2,35~60mg/ml IL-5;Further, the specific composition of induction medium is: DMEM medium, 5% autologous serum, 1% glutamine, 1% non-essential amino acid, 500~750IU/ml IL-2, 35~60mg/ml IL-5;
增殖培养基的具体组成为:Cellgro-SCGM培养基,5%自体血清,1%谷氨酰胺,1%非必需氨基酸,25~50ng/ml IL-15,0.5~1μg/ml GM-CSF。The specific composition of the proliferation medium is: Cellgro-SCGM medium, 5% autologous serum, 1% glutamine, 1% non-essential amino acids, 25~50ng/ml IL-15, 0.5~1μg/ml GM-CSF.
进一步的,步骤2)中根据培养瓶中培养基的体积,向培养瓶中加入维生素E的用量为10~20mg/ml,加入槲皮素的用量为15~20μg/ml。Further, in step 2), according to the volume of the culture medium in the culture bottle, the dosage of vitamin E added to the culture bottle is 10-20 mg/ml, and the dosage of quercetin is 15-20 μg/ml.
进一步的,步骤3)中根据培养瓶中培养基的体积,向培养瓶中加入谷胱甘肽的用量为5~10μg/ml,加入卟啉-α的用量为0.6~1μg/ml。Further, in step 3), according to the volume of the culture medium in the culture flask, the amount of glutathione added to the culture flask is 5-10 μg/ml, and the amount of porphyrin-α added is 0.6-1 μg/ml.
进一步的,步骤1)制备单个核细胞悬浮液的具体方法包括无菌采外周血,用缓冲液稀释外周血后,加入Ficoll分离液,离心后洗涤,得到外周血单个核细胞,将外周血单个核细胞按照一定的浓度用诱导培养基进行重悬,即完成。Further, the specific method for preparing the mononuclear cell suspension in step 1) includes aseptically collecting peripheral blood, diluting the peripheral blood with buffer, adding Ficoll separation medium, centrifuging and washing to obtain peripheral blood mononuclear cells, and separating the peripheral blood mononuclear cells. The nucleated cells are resuspended in induction medium according to a certain concentration, that is, complete.
本发明自然杀伤细胞体外培养方法,将整个培养过程分为诱导培养和增殖培养两个阶段,诱导培养采用透明质酸和CD16抗体对培养瓶预包被,培养过程中加入维生素E和槲皮素;增殖培养采用芝麻素和RetroNectin对培养瓶预包被,培养过程中加入谷胱甘肽和卟啉-α;培养瓶的包被成分、添加的助剂成分与各阶段培养基中的有效成分相互配合作用,协同增效促进NK细胞的活化和增殖,在提高NK细胞的扩增效率的同时,提高NK细胞的活性。The natural killer cell in vitro culture method of the invention divides the whole culture process into two stages: induction culture and proliferation culture. The culture flask is pre-coated with hyaluronic acid and CD16 antibody in the induction culture, and vitamin E and quercetin are added in the culture process. ; Proliferation culture uses sesamin and RetroNectin to pre-coat the culture flask, and adds glutathione and porphyrin-α during the culture process; the coating components of the culture flask, the added auxiliary components and the active ingredients in the medium at each stage They cooperate with each other and synergistically promote the activation and proliferation of NK cells. While improving the expansion efficiency of NK cells, the activity of NK cells is also improved.
具体实施方式Detailed ways
下面通过具体实施例对本发明的技术方案进行详细说明。The technical solutions of the present invention will be described in detail below through specific embodiments.
实施例1Example 1
一种自然杀伤细胞体外培养方法,包括以下操作步骤:A method for culturing natural killer cells in vitro, comprising the following steps:
1)配置培养基:1) Configure the culture medium:
A:诱导培养基:取DMEM培养基,加入5%自体血清,1%谷氨酰胺,1%非必需氨基酸,600IU/ml IL-2,45mg/ml IL-5;A: Induction medium: take DMEM medium, add 5% autologous serum, 1% glutamine, 1% non-essential amino acids, 600IU/ml IL-2, 45mg/ml IL-5;
B:增殖培养基:取Cellgro-SCGM培养基,加入5%自体血清,1%谷氨酰胺,1%非必需氨基酸,35ng/ml IL-15,0.7μg/ml GM-CSF;B: Proliferation medium: take Cellgro-SCGM medium, add 5% autologous serum, 1% glutamine, 1% non-essential amino acids, 35ng/ml IL-15, 0.7μg/ml GM-CSF;
其中非必要氨基酸为丝氨酸和丙氨酸;The non-essential amino acids are serine and alanine;
2)制备单个核细胞悬浮液:2) Prepare the mononuclear cell suspension:
无菌采外周血,用PBS缓冲液按照1:2的比稀释外周血;取离心管加入Ficoll分离液,然后将稀释后的外周血加入离心管中,离心后洗涤,得到外周血单个核细胞,将外周血单个核细胞按照5×105/ml的浓度用诱导培养基进行重悬;Aseptically collect peripheral blood, and dilute the peripheral blood with PBS buffer at a ratio of 1:2; take a centrifuge tube and add Ficoll separation medium, then add the diluted peripheral blood to the centrifuge tube, centrifuge and wash to obtain peripheral blood mononuclear cells , the peripheral blood mononuclear cells were resuspended in induction medium at a concentration of 5×10 5 /ml;
3)诱导培养:3) Induction culture:
A:培养瓶的包被:取生理盐水,加入透明质酸和CD16抗体,配置成含有5mg/ml透明质酸和7μg/ml CD16抗体的包被液,在培养瓶中加入7ml的PBS、1.5ml的包被液,4℃过夜后,弃去包被液,用PBS洗涤;A: Coating of culture flasks: take physiological saline, add hyaluronic acid and CD16 antibody, prepare a coating solution containing 5 mg/ml hyaluronic acid and 7 μg/ml CD16 antibody, add 7 ml of PBS, 1.5 ml of coating solution, after overnight at 4°C, discard the coating solution and wash with PBS;
B:将步骤2)制备的单个核细胞悬浮液接种至完成包被的培养瓶中,培养过程中及时补充诱导培养基,并且每间隔6小时,向培养瓶中加入维生素E至浓度为15mg/ml,槲皮素至浓度为18μg/ml,培养24小时得诱导培养悬浮液;B: Inoculate the mononuclear cell suspension prepared in step 2) into the coated culture flask, supplement the induction medium in time during the culture process, and add vitamin E to the culture flask every 6 hours to a concentration of 15 mg/ ml, quercetin to a concentration of 18 μg/ml, and cultured for 24 hours to obtain an induced culture suspension;
4)增殖培养:4) Proliferation culture:
A:培养瓶的包被:取生理盐水,加入芝麻素和RetroNectin,配置成含有55μg/ml芝麻素和7μg/ml RetroNectin的包被液,在培养瓶中加入8ml的PBS、1.5ml的包被液,4℃过夜后,弃去包被液,用PBS洗涤;A: Coating of culture flasks: take physiological saline, add sesamin and RetroNectin, prepare a coating solution containing 55μg/ml sesamin and 7μg/ml RetroNectin, add 8ml of PBS and 1.5ml of coating to the culture flask After overnight at 4°C, discard the coating solution and wash with PBS;
B:将步骤3)制备的诱导培养悬浮液接种至完成包被的培养瓶中,培养过程中及时补充增殖培养基,每间隔3天,向培养基中加入谷胱甘肽至其浓度为7μg/ml,卟啉-α至其浓度为0.8μg/ml,培养14天进行收获。B: Inoculate the induced culture suspension prepared in step 3) into the coated culture flask, replenish the proliferation medium in time during the culture process, and add glutathione to the medium every 3 days to a concentration of 7 μg /ml, porphyrin-α to a concentration of 0.8 μg/ml, cultured for 14 days and harvested.
实施例2Example 2
一种自然杀伤细胞的体外培养方法,包括以下操作步骤:A method for culturing natural killer cells in vitro, comprising the following steps:
1)配置培养基:1) Configure the culture medium:
A:诱导培养基:取DMEM培养基,加入5%自体血清,1%谷氨酰胺,1%非必需氨基酸,500IU/ml IL-2,60mg/ml IL-5;A: Induction medium: take DMEM medium, add 5% autologous serum, 1% glutamine, 1% non-essential amino acids, 500IU/ml IL-2, 60mg/ml IL-5;
B:增殖培养基:取Cellgro-SCGM培养基,加入5%自体血清,1%谷氨酰胺,1%非必需氨基酸,25ng/ml IL-15,1μg/ml GM-CSF;B: Proliferation medium: take Cellgro-SCGM medium, add 5% autologous serum, 1% glutamine, 1% non-essential amino acids, 25ng/ml IL-15, 1μg/ml GM-CSF;
其中非必要氨基酸为丝氨酸和丙氨酸;The non-essential amino acids are serine and alanine;
2)制备单个核细胞悬浮液:2) Prepare the mononuclear cell suspension:
无菌采外周血,用PBS缓冲液按照1:2的比稀释外周血;取离心管加入Ficoll分离液,然后将稀释后的外周血加入离心管中,离心后洗涤,得到外周血单个核细胞,将外周血单个核细胞按照5×105/ml的浓度用诱导培养基进行重悬;Aseptically collect peripheral blood, and dilute the peripheral blood with PBS buffer at a ratio of 1:2; take a centrifuge tube and add Ficoll separation medium, then add the diluted peripheral blood to the centrifuge tube, centrifuge and wash to obtain peripheral blood mononuclear cells , the peripheral blood mononuclear cells were resuspended in induction medium at a concentration of 5×10 5 /ml;
3)诱导培养:3) Induction culture:
A:培养瓶的包被:取生理盐水,加入透明质酸和CD16抗体,配置成含有3mg/ml透明质酸和8μg/ml CD16抗体的包被液,在培养瓶中加入10ml的PBS、2ml的包被液,4℃过夜后,弃去包被液,用PBS洗涤;A: Coating of culture flasks: take physiological saline, add hyaluronic acid and CD16 antibody, and prepare a coating solution containing 3 mg/ml hyaluronic acid and 8 μg/ml CD16 antibody, add 10 ml of PBS, 2 ml of PBS to the culture flask After overnight at 4°C, the coating solution was discarded and washed with PBS;
B:将步骤2)制备的单个核细胞悬浮液接种至完成包被的培养瓶中,培养过程中及时补充诱导培养基,并且每间隔6小时,向培养瓶中加入维生素E至浓度为10mg/ml,槲皮素至浓度为20μg/ml,培养24小时得诱导培养悬浮液;B: Inoculate the mononuclear cell suspension prepared in step 2) into the coated culture flask, supplement the induction medium in time during the culture process, and add vitamin E to the culture flask every 6 hours to a concentration of 10 mg/ ml, quercetin to a concentration of 20 μg/ml, and cultured for 24 hours to obtain an induced culture suspension;
4)增殖培养:4) Proliferation culture:
A:培养瓶的包被:取生理盐水,加入芝麻素和RetroNectin,配置成含有50μg/ml芝麻素和8μg/ml RetroNectin的包被液,在培养瓶中加入5ml的PBS、1ml的包被液,4℃过夜后,弃去包被液,用PBS洗涤;A: Coating of culture flasks: take physiological saline, add sesamin and RetroNectin, prepare a coating solution containing 50μg/ml sesamin and 8μg/ml RetroNectin, add 5ml of PBS and 1ml of coating solution to the culture flask , after overnight at 4°C, discard the coating solution and wash with PBS;
B:将步骤3)制备的诱导培养悬浮液接种至完成包被的培养瓶中,培养过程中及时补充增殖培养基,每间隔2天,向培养基中加入谷胱甘肽至其浓度为5μg/ml,卟啉-α至其浓度为1μg/ml,培养14天进行收获。B: Inoculate the induced culture suspension prepared in step 3) into the coated culture flask, replenish the proliferation medium in time during the culture process, and add glutathione to the medium every 2 days to a concentration of 5 μg /ml, porphyrin-α to a concentration of 1 μg/ml, cultured for 14 days and harvested.
实施例3Example 3
一种自然杀伤细胞的体外培养方法,包括以下操作步骤:A method for culturing natural killer cells in vitro, comprising the following steps:
1)配置培养基:1) Configure the culture medium:
A:诱导培养基:取DMEM培养基,加入5%自体血清,1%谷氨酰胺,1%非必需氨基酸,750IU/ml IL-2,35mg/ml IL-5;A: Induction medium: take DMEM medium, add 5% autologous serum, 1% glutamine, 1% non-essential amino acids, 750IU/ml IL-2, 35mg/ml IL-5;
B:增殖培养基:取Cellgro-SCGM培养基,加入5%自体血清,1%谷氨酰胺,1%非必需氨基酸,50ng/ml IL-15,0.5μg/ml GM-CSF;B: Proliferation medium: take Cellgro-SCGM medium, add 5% autologous serum, 1% glutamine, 1% non-essential amino acids, 50ng/ml IL-15, 0.5μg/ml GM-CSF;
其中非必要氨基酸为丝氨酸和丙氨酸;The non-essential amino acids are serine and alanine;
2)制备单个核细胞悬浮液:2) Prepare the mononuclear cell suspension:
无菌采外周血,用PBS缓冲液按照1:2的比稀释外周血;取离心管加入Ficoll分离液,然后将稀释后的外周血加入离心管中,离心后洗涤,得到外周血单个核细胞,将外周血单个核细胞按照5×105/ml的浓度用诱导培养基进行重悬;Aseptically collect peripheral blood, and dilute the peripheral blood with PBS buffer at a ratio of 1:2; take a centrifuge tube and add Ficoll separation medium, then add the diluted peripheral blood to the centrifuge tube, centrifuge and wash to obtain peripheral blood mononuclear cells , the peripheral blood mononuclear cells were resuspended in induction medium at a concentration of 5×10 5 /ml;
3)诱导培养:3) Induction culture:
A:培养瓶的包被:取生理盐水,加入透明质酸和CD16抗体,配置成含有6mg/ml透明质酸和5μg/ml CD16抗体的包被液,在培养瓶中加入5ml的PBS、1.5ml的包被液,4℃过夜后,弃去包被液,用PBS洗涤;A: Coating of culture flasks: Take physiological saline, add hyaluronic acid and CD16 antibody, and prepare a coating solution containing 6 mg/ml hyaluronic acid and 5 μg/ml CD16 antibody, add 5 ml of PBS, 1.5 ml of PBS to the culture flask ml of coating solution, after overnight at 4°C, discard the coating solution and wash with PBS;
B:将步骤2)制备的单个核细胞悬浮液接种至完成包被的培养瓶中,培养过程中及时补充诱导培养基,并且每间隔6小时,向培养瓶中加入维生素E至浓度为20mg/ml,槲皮素至浓度为15μg/ml,培养24小时得诱导培养悬浮液;B: Inoculate the mononuclear cell suspension prepared in step 2) into the coated culture flask, supplement the induction medium in time during the culture process, and add vitamin E to the culture flask every 6 hours to a concentration of 20 mg/ ml, quercetin to a concentration of 15μg/ml, and cultured for 24 hours to obtain an induced culture suspension;
4)增殖培养:4) Proliferation culture:
A:培养瓶的包被:取生理盐水,加入芝麻素和RetroNectin,配置成含有60μg/ml芝麻素和5μg/ml RetroNectin的包被液,在培养瓶中加入10ml的PBS、2ml的包被液,4℃过夜后,弃去包被液,用PBS洗涤;A: Coating of culture flasks: take physiological saline, add sesamin and RetroNectin, and prepare a coating solution containing 60 μg/ml sesamin and 5 μg/ml RetroNectin, add 10 ml of PBS and 2 ml of coating solution to the culture flask , after overnight at 4°C, discard the coating solution and wash with PBS;
B:将步骤3)制备的诱导培养悬浮液接种至完成包被的培养瓶中,培养过程中及时补充增殖培养基,每间隔3天,向培养基中加入谷胱甘肽至其浓度为10μg/ml,卟啉-α至其浓度为0.6μg/ml,培养14天进行收获。B: Inoculate the induced culture suspension prepared in step 3) into the coated culture flask, replenish the proliferation medium in time during the culture process, and add glutathione to the medium every 3 days to a concentration of 10 μg /ml, porphyrin-α to a concentration of 0.6 μg/ml, cultured for 14 days and harvested.
对比例1Comparative Example 1
本对比例与实施例1的不同之处在于,用芝麻素和RetroNectin包被诱导培养用培养瓶,用透明质酸和CD16抗体包被增殖培养用培养瓶,其他同实施例1。The difference between this comparative example and Example 1 is that the culture flask for induction culture is coated with sesamin and RetroNectin, and the culture flask for proliferation culture is coated with hyaluronic acid and CD16 antibody, and the others are the same as in Example 1.
对比例2Comparative Example 2
本对比例与实施例1的不同之处在于,在诱导培养过程中加入谷胱甘肽和卟啉-α替代维生素E和槲皮素,在增殖培养过程中加入维生素E和槲皮素替代谷胱甘肽和卟啉-α。The difference between this comparative example and Example 1 is that glutathione and porphyrin-α were added to replace vitamin E and quercetin during the induction culture, and vitamin E and quercetin were added to replace the glutathione during the proliferation culture. Sathione and Porphyrin-alpha.
对比例3Comparative Example 3
本对比例与实施例1的不同之处在于,诱导培养用培养瓶包被过程中省去使用透明质酸,其他同实施例1。The difference between this comparative example and Example 1 is that the use of hyaluronic acid is omitted in the coating process of the culture flask for induction culture, and the other is the same as that of Example 1.
对比例4Comparative Example 4
本对比例与实施例1的不同之处在于,增殖培养用培养瓶包被过程中省去使用芝麻素,在增殖培养基中加入等量的芝麻素,其他同实施例1。The difference between this comparative example and Example 1 is that the use of sesamin was omitted during the coating process of the culture bottle for proliferation culture, and an equal amount of sesamin was added to the proliferation medium, and the others were the same as in Example 1.
试验例1 细胞增殖总数量对比Test Example 1 Comparison of the total number of cell proliferation
配置pH=7.0~7.2,质量浓度为0.4%的台盼蓝溶液,分别取实施例1~3、对比例1~4,14天增殖培养后的NK细胞悬液,加入等体积的台盼蓝混合,细胞染色后,细胞计数板计数细胞总数量,结果显示实施例1>实施例2≈实施例3>对比例3>对比例4≈对比例1>对比例2,并且实施例14天增殖培养后的细胞总数量是对比例1的5倍,是对比例2的10倍。Configure a trypan blue solution with pH=7.0~7.2 and a mass concentration of 0.4%, respectively take the NK cell suspensions of Examples 1~3, Comparative Examples 1~4, and 14 days of proliferation and culture, and add an equal volume of trypan blue. After mixing, the cells were stained, and the total number of cells was counted on the cytometer. The results showed that Example 1> Example 2 ≈ Example 3> Comparative Example 3> Comparative Example 4 ≈ Comparative Example 1> Comparative Example 2, and Example 14 days of proliferation The total number of cells after culture was 5 times that of Comparative Example 1 and 10 times that of Comparative Example 2.
试验例2 细胞活性对比Test Example 2 Cell Viability Comparison
用96孔平底培养板,设实验孔、单纯效应细胞孔、单纯靶细胞孔各3个,并设空白孔,于实验孔及单纯靶细胞孔,加入K562。在实验孔及单纯效应细胞孔中各加入实施例1增殖培养14天的NK细胞,设定效靶比为40:1,培养24小时,加入WST 20μl,继续培养4h,酶标仪检测OD值,杀伤活性(%)=[1-(实验孔OD值-单纯效应细胞组OD值)×单纯靶细胞OD值] ×100%;A 96-well flat-bottom culture plate was used to set up three experimental wells, three pure effector cell wells and three pure target cell wells, and set up blank wells. K562 was added to the experimental wells and pure target cell wells. NK cells proliferated and cultured for 14 days in Example 1 were added to the experimental wells and the simple effector cell wells, the effector-target ratio was set to 40:1, cultured for 24 hours, 20 μl of WST was added, and the culture was continued for 4 hours, and the OD value was detected by a microplate reader. , killing activity (%)=[1-(OD value of experimental well-OD value of effector cell group)×OD value of pure target cell]×100%;
按照上述同样的方法,分别计算对比例1~4增殖培养14天后的NK细胞对K562的杀伤活性。According to the same method as above, the killing activities of NK cells in Comparative Examples 1 to 4 after 14 days of proliferation and culture were calculated respectively to K562.
对比不同培养方法获得的NK细胞的杀伤活性,结果显示,实施例1>对比例3>对比例4>对比例1>对比例2。Comparing the killing activities of NK cells obtained by different culture methods, the results show that Example 1>Comparative Example 3>Comparative Example 4>Comparative Example 1>Comparative Example 2.
最后应说明的是:以上实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的精神和范围。Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, but not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those of ordinary skill in the art should understand that it can still be The technical solutions described in the foregoing embodiments are modified, or some technical features thereof are equivalently replaced; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010163641.4A CN111286488B (en) | 2020-03-10 | 2020-03-10 | In vitro culture method of natural killer cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010163641.4A CN111286488B (en) | 2020-03-10 | 2020-03-10 | In vitro culture method of natural killer cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111286488A true CN111286488A (en) | 2020-06-16 |
CN111286488B CN111286488B (en) | 2021-04-02 |
Family
ID=71027023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010163641.4A Active CN111286488B (en) | 2020-03-10 | 2020-03-10 | In vitro culture method of natural killer cells |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111286488B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112266900A (en) * | 2020-10-30 | 2021-01-26 | 广东康盾生物工程技术有限公司 | CAR-NK cell culture method |
CN114874984A (en) * | 2022-06-16 | 2022-08-09 | 杭州中赢生物医疗科技有限公司 | Method for in vitro induction amplification of NK cells by adopting plant extract |
CN116218781A (en) * | 2022-12-30 | 2023-06-06 | 四川阿思科力生物科技有限公司 | ROBO1 CAR-NK92 cell recovery medium, kit and recovery culture method |
CN116218781B (en) * | 2022-12-30 | 2025-08-01 | 四川阿思科力生物科技有限公司 | ROBO1 CAR-NK92 cell resuscitating medium, kit and resuscitating culture method |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007136673A2 (en) * | 2006-05-19 | 2007-11-29 | Medistem Laboratories, Inc. | Treatment of disc degenerative disease and compositions for same |
CN101519646A (en) * | 2009-02-06 | 2009-09-02 | 上海德嘉生物科技有限公司 | CIK cell, as well as preparation method and cell preparation thereof |
WO2012128622A1 (en) * | 2011-03-18 | 2012-09-27 | Ipd-Therapeutics B.V. | Generation of nk cells and nk-cell progenitors |
WO2015137595A1 (en) * | 2014-03-14 | 2015-09-17 | 동아대학교 산학협력단 | Nano-micro hybrid polymer fiber-based structure for cell culture, and assay chip containing same |
CN105861435A (en) * | 2016-05-11 | 2016-08-17 | 南京华奥生物医药技术有限公司 | In-vitro amplification method of natural killer cells (NK) |
CN106011061A (en) * | 2016-08-04 | 2016-10-12 | 广东省第二人民医院 | In-vitro large-scale amplification method of natural killer cells |
CN108004211A (en) * | 2017-12-22 | 2018-05-08 | 深圳市赛欧细胞生物科技有限公司 | A kind of method of Activated in Vitro amplifying natural killer cell |
CN109294985A (en) * | 2018-10-25 | 2019-02-01 | 江苏普瑞康生物医药科技有限公司 | A culture medium system for in vitro expansion of NK cells and method for in vitro expansion of NK cells |
-
2020
- 2020-03-10 CN CN202010163641.4A patent/CN111286488B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007136673A2 (en) * | 2006-05-19 | 2007-11-29 | Medistem Laboratories, Inc. | Treatment of disc degenerative disease and compositions for same |
CN101519646A (en) * | 2009-02-06 | 2009-09-02 | 上海德嘉生物科技有限公司 | CIK cell, as well as preparation method and cell preparation thereof |
WO2012128622A1 (en) * | 2011-03-18 | 2012-09-27 | Ipd-Therapeutics B.V. | Generation of nk cells and nk-cell progenitors |
WO2015137595A1 (en) * | 2014-03-14 | 2015-09-17 | 동아대학교 산학협력단 | Nano-micro hybrid polymer fiber-based structure for cell culture, and assay chip containing same |
CN105861435A (en) * | 2016-05-11 | 2016-08-17 | 南京华奥生物医药技术有限公司 | In-vitro amplification method of natural killer cells (NK) |
CN106011061A (en) * | 2016-08-04 | 2016-10-12 | 广东省第二人民医院 | In-vitro large-scale amplification method of natural killer cells |
CN108004211A (en) * | 2017-12-22 | 2018-05-08 | 深圳市赛欧细胞生物科技有限公司 | A kind of method of Activated in Vitro amplifying natural killer cell |
CN109294985A (en) * | 2018-10-25 | 2019-02-01 | 江苏普瑞康生物医药科技有限公司 | A culture medium system for in vitro expansion of NK cells and method for in vitro expansion of NK cells |
Non-Patent Citations (2)
Title |
---|
ATSUSHI KUWAHARA ET AL: "Functional Domain Order of an Anti-EGFR x Anti-CD16 Bispecific Diabody Involving NK Cell Activation", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 * |
赵晋 等: "抗氧化剂对脐血自然杀伤细胞活性及化学发光的影响", 《第四军医大学学报》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112266900A (en) * | 2020-10-30 | 2021-01-26 | 广东康盾生物工程技术有限公司 | CAR-NK cell culture method |
CN114874984A (en) * | 2022-06-16 | 2022-08-09 | 杭州中赢生物医疗科技有限公司 | Method for in vitro induction amplification of NK cells by adopting plant extract |
CN114874984B (en) * | 2022-06-16 | 2024-05-03 | 杭州中赢生物医疗科技有限公司 | Method for in-vitro induction amplification of NK cells by adopting plant extracts |
CN116218781A (en) * | 2022-12-30 | 2023-06-06 | 四川阿思科力生物科技有限公司 | ROBO1 CAR-NK92 cell recovery medium, kit and recovery culture method |
CN116218781B (en) * | 2022-12-30 | 2025-08-01 | 四川阿思科力生物科技有限公司 | ROBO1 CAR-NK92 cell resuscitating medium, kit and resuscitating culture method |
Also Published As
Publication number | Publication date |
---|---|
CN111286488B (en) | 2021-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101748096B (en) | Sub totipotential stem cell and preparation method and application thereof | |
JP7549355B2 (en) | Methods for expanding mesenchymal stromal cells | |
CN102876630B (en) | Method for efficiently separating and expanding mesenchymal stem cells in human umbilical cord blood | |
CN114507640B (en) | Culture method and application of CIK cells with high proliferation capacity and high cytotoxicity | |
CN113692282A (en) | Bioactive substance composition, serum-free culture medium containing composition and application of serum-free culture medium | |
CN111286488A (en) | In vitro culture method of natural killer cells | |
CN116490607A (en) | Tumor infiltrating lymphocyte culture medium and its application | |
CN112608896A (en) | NK cell culture method and application thereof | |
CN113249321A (en) | Peripheral blood NK cell culture method | |
CN113181215B (en) | Bone marrow mesenchymal stem cell exosome preparation and application thereof in promoting hematopoietic injury recovery | |
CN112080469B (en) | Application of T1 peptide in promoting cord blood hematopoietic stem cell proliferation in vitro | |
WO2022198805A1 (en) | Method for inducing in vitro differentiation of hemopoietic stem cells into regulatory t cells | |
CN118620839A (en) | A culture medium and method for improving NK cell proliferation and killing activity in a serum-free environment | |
CN109954139B (en) | Application of matrine as immunoadjuvant in preparation of gastric cancer dendritic cell vaccine | |
CN102925411A (en) | Application of vitamin C in in-vitro expansion of number of effector memory T cells | |
CN108441473B (en) | Method for enriching CD8+ T cells in vitro | |
CN111849897B (en) | In vitro activation method for cell factor induced killer cells | |
CN115197907B (en) | Preparation method of stimulated cells for in-vitro culture of autologous or universal NK cells | |
CN1302102C (en) | Method for preparing megakaryocytic preparation by amplifying macronucleus ancestral cell and mature megacaryocyte and use | |
CN115247149A (en) | Culture medium composition suitable for NK cells and culture method | |
CN108517313B (en) | Serum/plasma substitute for culturing and amplifying dental pulp stem cells | |
RU2418855C1 (en) | Medium for cultivation of multipotent stromal cells from human adipose tissue and method of cultivation of said cells with its application | |
Bukharova et al. | Tissue engineering construct on the basis of multipotent stromal adipose tissue cells and osteomatrix for regeneration of the bone tissue | |
Feng et al. | Application of a Magnetic Platform in α6 Integrin-Positive iPSC-TM Purification. Bioengineering 2023, 10, 410 | |
CN112779218A (en) | Culture medium and culture method for primary culture of tumor infiltrating mast cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230919 Address after: Room 111, No. 319 Shenjia Road, Gongshu District, Hangzhou City, Zhejiang Province, 310000 Patentee after: Hangzhou Houwu Biopharmaceutical Technology Co.,Ltd. Address before: 450000 floor 1-6, unit 1, building y07, No.11, Changchun Road, high tech Industrial Development Zone, Zhengzhou City, Henan Province Patentee before: Henan Qiaochuang Life Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20241207 Address after: 450000 floor 1-6, unit 1, building y07, No.11, Changchun Road, high tech Industrial Development Zone, Zhengzhou City, Henan Province Patentee after: Henan Qiaochuang Life Technology Co.,Ltd. Country or region after: China Address before: Room 111, No. 319 Shenjia Road, Gongshu District, Hangzhou City, Zhejiang Province, 310000 Patentee before: Hangzhou Houwu Biopharmaceutical Technology Co.,Ltd. Country or region before: China |